Ditchcarbon
  • Contact
  1. Organizations
  2. Indivior
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated a month ago

Indivior Sustainability Profile

Company website

Indivior PLC, a global leader in addiction treatment, is headquartered in the United States and operates extensively across North America and Europe. Founded in 2014, the company has rapidly established itself within the pharmaceutical industry, focusing on innovative solutions for opioid dependence and other substance use disorders. Indivior is renowned for its flagship product, Suboxone, which combines buprenorphine and naloxone to effectively manage opioid addiction while minimising misuse potential. This unique formulation has positioned Indivior as a key player in the market, contributing to significant advancements in addiction therapy. With a commitment to improving patient outcomes, Indivior has achieved notable milestones, including regulatory approvals and partnerships that enhance its service offerings. The company continues to lead the way in addressing the global opioid crisis, solidifying its reputation as a trusted provider in the addiction treatment sector.

DitchCarbon Score

How does Indivior's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

46

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

31

Industry Benchmark

Indivior's score of 46 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.

64%

Let us know if this data was useful to you

Indivior's reported carbon emissions

In 2024, Indivior reported total carbon emissions of approximately 136,000,000 kg CO2e globally, comprising 6,986,000 kg CO2e from Scope 1, 5,174,000 kg CO2e from Scope 2 (market-based), and a significant 129,350,000 kg CO2e from Scope 3 emissions. In the UK, the company’s emissions totalled about 4,102,000 kg CO2e, with 289,000 kg CO2e from Scope 1, 368,000 kg CO2e from Scope 2 (market-based), and 3,445,000 kg CO2e from Scope 3. Indivior has set ambitious climate commitments, aiming for a 100% transition to hybrid vehicles by the end of 2026, which applies to both Scope 1 and Scope 2 emissions. Additionally, the company is optimistic about achieving net-zero emissions by 2050, contingent on a globally coordinated effort for decarbonisation. This long-term target reflects a commitment to sustainability and aligns with industry standards for climate action. The emissions data is not cascaded from any parent organisation, and all figures are directly reported by Indivior PLC. The company continues to monitor and report its emissions across all scopes, demonstrating transparency and accountability in its climate strategy.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

201920202021202220232024
Scope 1
699,000
000,000
0,000,000
0,000,000
0,000,000
0,000,000
Scope 2
2,592,000
0,000,000
0,000,000
0,000,000
0,000,000
0,000,000
Scope 3
140,000
000,000
-
-
000,000,000
000,000,000

How Carbon Intensive is Indivior's Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Indivior's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Indivior's Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Indivior is in US, which has a low grid carbon intensity relative to other regions.

Indivior's Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Indivior has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Indivior's Emissions with Industry Peers

RECORDATI

LU
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Sage Therapeutics, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Cosmo Pharmaceuticals N.V.

IE
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Almirall

ES
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Novartis

CH
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Gilead Sciences

US
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251104.2
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy